Table_2_The Serum MicroRNA Signatures for Pancreatic Cancer Detection and Operability Evaluation.XLSX

Pancreatic cancer (PC) has high morbidity and mortality. It is the fourth leading cause of cancer death. Its diagnosis and treatment are difficult. Liquid biopsy makes early diagnosis of pancreatic cancer possible. We analyzed the expression profiles of 2,555 serum miRNAs in 100 pancreatic cancer patients and 150 healthy controls. With advanced feature selection methods, we identified 13 pancreatic cancer signature miRNAs that can classify the pancreatic cancer patients and healthy controls. For pancreatic cancer treatment, operation is still the first choice. But many pancreatic cancer patients are already inoperable. Therefore, we compared the 79 inoperable and 21 operable patients and identified 432 miRNAs that can predict whether a pancreatic cancer patient was operable. The functional analysis of the 13 pancreatic cancer signatures and the 432 operability miRNAs revealed the molecular mechanisms of pancreatic cancer and shield light on the diagnosis and therapy of pancreatic cancer in clinical practice.

胰腺癌（PC）具有高发病率和死亡率，位居癌症死亡原因第四位。其诊断与治疗均较为困难。液体活检技术使得胰腺癌的早期诊断成为可能。本研究对100名胰腺癌患者和150名健康对照者的2,555种血清miRNA表达谱进行了分析。通过先进的特征选择方法，我们确定了13个能够区分胰腺癌患者与健康对照者的胰腺癌特征性miRNA。在胰腺癌治疗方面，手术仍然是最优先选择。然而，许多胰腺癌患者已处于不可手术状态。因此，我们对比了79名不可手术患者和21名可手术患者，并识别出432种可以预测胰腺癌患者是否可手术的miRNA。对这13个胰腺癌特征性miRNA和432个可手术性miRNA的功能分析揭示了胰腺癌的分子机制，并为临床实践中胰腺癌的诊断与治疗提供了新的见解。